Changeflow GovPing Pharma & Drug Safety Controlled Substance Importer Registration Appl...
Routine Notice Added Final

Controlled Substance Importer Registration Application - Sterling Wisconsin LLC

Favicon for www.regulations.gov Regs.gov: Drug Enforcement Administration
Published
Detected
Email

Summary

The Drug Enforcement Administration published notice that Sterling Wisconsin, LLC applied for registration as a Schedule I controlled substance importer (drug code 7431 - 5-Methoxy-N,N-dimethyltryptamine). The application was filed January 27, 2026. Interested parties may submit comments or hearing requests by May 1, 2026.

Published by DEA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

DEA published a notice of application for Sterling Wisconsin, LLC to be registered as an importer of 5-Methoxy-N,N-dimethyltryptamine (drug code 7431, Schedule I). The company plans to import the controlled substance as bulk Active Pharmaceutical Ingredient for internal research, clinical investigational studies, and analytical purposes. The registration would not authorize import of FDA-approved or non-approved finished dosage forms for commercial sale.

Registered bulk manufacturers of affected controlled substance classes and other interested parties may submit electronic comments or objections, or request a hearing on the application, on or before May 1, 2026. Comments must be submitted through regulations.gov. No compliance actions are required of regulated entities unless they wish to object to this registration.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

ACTION:

Notice of application.

SUMMARY:

Sterling Wisconsin, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to

     Supplementary Information
     listed below for further drug information.

DATES:

Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on
or objections to the issuance of the proposed registration on or before May 1, 2026. Such persons may also file a written
request for a hearing on the application on or before May 1, 2026.

ADDRESSES:

The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file
for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive
a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit
the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ,
8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration,
Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION:

In accordance with 21 CFR 1301.34(a), this is notice that on January 27, 2026, Sterling Wisconsin, LLC, W130N10497 Washington
Drive, Germantown, Wisconsin 53022-4448, applied to be registered as an importer of the following basic class(es) of controlled
substance(s):

Controlled substance Drug code Schedule
5-Methoxy-N,N-dimethyltryptamine 7431 I

The company plans to import this controlled substance as bulk Active Pharmaceutical Ingredient to bulk manufacture in support
of internal research, clinical investigational studies, and analytical purposes. No other activity for this drug code is authorized
for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved
finished dosage forms for commercial sale.

Thomas Prevoznik, Deputy Assistant Administrator. [FR Doc. 2026-06260 Filed 3-31-26; 8:45 am] BILLING CODE P

Download File

Download

CFR references

21 CFR 1301.34(a)

Get daily alerts for Regs.gov: Drug Enforcement Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from DEA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
DEA
Published
March 31st, 2026
Comment period closes
May 1st, 2026 (14 days)
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
FR Doc. 2026-06260
Docket
DEA-2026-0533

Who this affects

Applies to
Drug manufacturers Importers and exporters
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Controlled Substance Import/Export
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Compliance
Topics
Controlled Substances Import Controls

Get alerts for this source

We'll email you when Regs.gov: Drug Enforcement Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!